Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Melanoma
Related studies linked through entity extraction aliases.
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients
- Status
- UNKNOWN
- Phase
- PHASE1
fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth
- Status
- COMPLETED
- Phase
- PHASE1
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
- Status
- TERMINATED
- Phase
- PHASE1
Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas
- Status
- TERMINATED
- Phase
- NA
Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab
- Status
- COMPLETED
- Phase
- N/A
Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.
- Status
- COMPLETED
- Phase
- N/A
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy
- Status
- UNKNOWN
- Phase
- N/A
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
- Status
- TERMINATED
- Phase
- PHASE1
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
myDC/pDC in Stage III Melanoma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)
- Status
- COMPLETED
- Phase
- PHASE2
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)
- Status
- COMPLETED
- Phase
- PHASE1